Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding
specificity to CD20. It was the first therapeutic antibody approved for oncology patients and …

To date, no consensus exists among stakeholders about switching patients between
reference biological products (RPs) and biosimilars, which may have been curbing the …

Background The efficacy, safety and immunogenicity risk of switching between an originator
biologic and a biosimilar or from one biosimilar to another are of potential concern …

Importance The high cost of biologics used to treat cancer has been an increasing burden in
the world. In China, the recent approval of cancer biosimilar drugs to resolve this problem is …

Biologics play a key role in cancer treatment and are principal components of many
therapeutic regimens. However, they require complex manufacturing processes, resulting in …

Rituximab improved the prognosis of all B-cell derived lymphoproliferative diseases, but
despite 20 years of intensive use, it remains a drug with a number of still obscure …

Background There are no clinical trials involving patients with diffuse large B-cell lymphoma
(DLBCL) in sub-Saharan Africa since antiretroviral therapy (ART) for HIV became widely …

Different manufacturing processes and storage conditions of biotherapeutics can lead to a
significant variability in drug products arising from chemical and enzymatic post-translational …

Healthcare systems worldwide are struggling to find ways to fund the cost of innovative
treatments such as gene therapies, regenerative medicine, and monoclonal antibodies …

Rituximab has been revolutionized and validated CD20 targeting monoclonal antibody.
Although, it is widely used for lymphoma therapy and many patients have been benefited …